Advisors' Inner Circle Fund III has submitted its annual filing under the 24F-2NT form, revealing key insights into its sales and redemption activities for the fiscal year ending July 31, 2026. This filing is significant as it provides stakeholders with a clearer picture of the fund's performance and liquidity status.
According to the filing, the fund reported an aggregate sale price of securities sold amounting to $32,947,440. In contrast, the total price of securities redeemed or repurchased during the fiscal year was $23,637,495. This results in a net sales figure of zero, indicating that the fund's sales and redemptions balanced each other out during this period.
Advisors' Inner Circle Fund III operates as an investment company, primarily managing mutual funds. The company is based in Oaks, Pennsylvania, and has a history of providing various investment products to its clients. The fund is registered under the Investment Company Act with a file number of 811-22920.
The filing also highlights that the total available redemption credits for future use amount to $187,255,657, while the redemption credits available for use in future years are noted as ($154,308,217). This information is essential for investors as it indicates the fund's liquidity and capacity to manage future redemptions.
Andrew Metzger, the Treasurer, Controller, and Chief Financial Officer, signed the filing on October 27, 2026, confirming the accuracy of the reported figures.
As the investment management industry continues to evolve, this filing may influence how competitors assess their own strategies in response to market conditions. The balance between sales and redemptions could prompt other funds to reevaluate their liquidity management practices.
Looking ahead, the filing does not specify what actions will be taken next, leaving stakeholders to speculate on the future direction of Advisors' Inner Circle Fund III.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






